Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK)
Hangzhou, CN
MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.67% | -4.68% | -8.14% | -4.92% | +8.10% | -7.44% | +30.37% | +18.39% | -75.93% | -75.93% | -75.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | -1 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+91.2% ★ Q4'25: +191.3% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+166.7% ★ Q4'25: +144.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+1.5% Q4'25: +5.3% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+2.7% Q4'25: +8.9% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+3.2% Q4'25: +26.2% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-4.6% ★ Q4'25: -10.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.15× ★ Q4'25: 0.54× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
151.40M
est: 175.89M (-13.9%)
|
173.54M
est: 201.92M (-14.1%)
|
248.35M
est: 272.76M (-9.0%)
|
345.62M
est: 351.79M (-1.8%)
|
660.79M
est: 649.75M (+1.7%)
|
926.22M
904.27M – 948.18M
+42.6% YoY
|
1.20B
1.17B – 1.25B
+29.8% YoY
|
1.53B
1.49B – 1.58B
+27.0% YoY
|
| EBITDA |
-39.80M
est: -105.19M (+62.2%)
|
-110.19M
est: -120.77M (+8.8%)
|
-184.12M
est: -106.19M (-73.4%)
|
-121.38M
est: -136.95M (+11.4%)
|
29.02M
est: -252.95M (+111.5%)
|
-360.58M
-369.13M – -352.04M
-42.6% YoY
|
-468.01M
-487.82M – -454.05M
-29.8% YoY
|
-594.47M
-614.78M – -578.34M
-27.0% YoY
|
| EBIT |
-48.14M
est: -111.83M (+57.0%)
|
-120.34M
est: -128.38M (+6.3%)
|
-195.29M
est: -117.39M (-66.4%)
|
-131.75M
est: -151.41M (+13.0%)
|
17.82M
est: -279.65M (+106.4%)
|
-398.64M
-408.09M – -389.19M
-42.6% YoY
|
-517.41M
-539.31M – -501.97M
-29.8% YoY
|
-657.22M
-679.66M – -639.38M
-27.0% YoY
|
| Net Income |
-48.18M
est: -22.91M (-110.3%)
|
-35.04M
est: -41.83M (+16.2%)
|
-125.02M
est: -134.03M (+6.7%)
|
-63.12M
est: -76.61M (+17.6%)
|
40.15M
est: 36.06M (+11.3%)
|
86.80M
83.36M – 90.24M
+140.7% YoY
|
139.14M
107.96M – 183.54M
+60.3% YoY
|
219.67M
212.43M – 226.91M
+57.9% YoY
|
| SGA |
94.27M
est: 120.97M (-22.1%)
|
158.99M
est: 138.87M (+14.5%)
|
161.52M
est: 157.41M (+2.6%)
|
151.73M
est: 203.01M (-25.3%)
|
170.02M
est: 374.96M (-54.7%)
|
534.51M
521.84M – 547.18M
+42.6% YoY
|
693.76M
673.07M – 723.13M
+29.8% YoY
|
881.22M
857.30M – 911.32M
+27.0% YoY
|
| EPS |
-0.13
est: -0.05 (-138.8%)
|
-0.08
est: -0.10 (+19.5%)
|
-0.29
est: -0.33 (+13.0%)
|
-0.15
est: -0.19 (+21.0%)
|
0.10
est: 0.09 (+11.2%)
|
0.22
0.21 – 0.22
+139.2% YoY
|
0.36
0.27 – 0.46
+68.7% YoY
|
0.55
0.53 – 0.57
+50.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yonghui Shi | Senior Vice President, Chief Strategy & Development Officer, Joint Company Secretary and Executive Director | 2M | — |
| Pan Zheng | Executive Chairman & Chief Executive Officer | 989.4K | — |
| Xiu Liu | Executive Director & Financial Controller | 844.7K | female |
| Fei Yu | Chief Technology Officer & Executive Director | 731.0K | — |
| Fangling Xu | Vice President & Head of Administration Department | 106.3K | female |
| Pik Man Chu | Joint Company Secretary | — | female |
| Yi Lan | Vice President of Marketing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2235.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
